Collegium Pharmaceutical Inc (COLL) Chairman Michael Thomas Heffernan Sells 20,000 Shares

Collegium Pharmaceutical Inc (NASDAQ:COLL) Chairman Michael Thomas Heffernan sold 20,000 shares of Collegium Pharmaceutical stock in a transaction that occurred on Friday, January 19th. The shares were sold at an average price of $22.50, for a total transaction of $450,000.00. Following the sale, the chairman now owns 538,987 shares of the company’s stock, valued at $12,127,207.50. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.

Michael Thomas Heffernan also recently made the following trade(s):

  • On Wednesday, November 15th, Michael Thomas Heffernan sold 50,000 shares of Collegium Pharmaceutical stock. The shares were sold at an average price of $15.53, for a total transaction of $776,500.00.

Collegium Pharmaceutical Inc (NASDAQ COLL) traded up $3.17 on Friday, hitting $23.38. 1,660,607 shares of the company traded hands, compared to its average volume of 595,466. Collegium Pharmaceutical Inc has a 1 year low of $7.37 and a 1 year high of $23.53. The firm has a market cap of $880.72 and a PE ratio of -7.87.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its earnings results on Wednesday, November 8th. The specialty pharmaceutical company reported ($0.45) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.73) by $0.28. Collegium Pharmaceutical had a negative net margin of 447.83% and a negative return on equity of 77.11%. The firm had revenue of $11.95 million during the quarter, compared to analysts’ expectations of $5.31 million. During the same period in the previous year, the business posted ($1.13) EPS. The business’s revenue was up 2814.6% compared to the same quarter last year. sell-side analysts forecast that Collegium Pharmaceutical Inc will post -2.52 earnings per share for the current year.

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Acadian Asset Management LLC acquired a new position in shares of Collegium Pharmaceutical in the 4th quarter valued at $176,000. Schwab Charles Investment Management Inc. lifted its stake in shares of Collegium Pharmaceutical by 13.5% in the 4th quarter. Schwab Charles Investment Management Inc. now owns 51,119 shares of the specialty pharmaceutical company’s stock valued at $944,000 after purchasing an additional 6,083 shares during the period. Benjamin F. Edwards & Company Inc. lifted its stake in shares of Collegium Pharmaceutical by 87.5% in the 4th quarter. Benjamin F. Edwards & Company Inc. now owns 7,500 shares of the specialty pharmaceutical company’s stock valued at $138,000 after purchasing an additional 3,500 shares during the period. Pura Vida Investments LLC acquired a new position in shares of Collegium Pharmaceutical in the 3rd quarter valued at $1,229,000. Finally, Wells Fargo & Company MN lifted its stake in shares of Collegium Pharmaceutical by 12.8% in the 3rd quarter. Wells Fargo & Company MN now owns 45,254 shares of the specialty pharmaceutical company’s stock valued at $475,000 after purchasing an additional 5,136 shares during the period. Hedge funds and other institutional investors own 79.98% of the company’s stock.

COLL has been the subject of several research reports. Needham & Company LLC lifted their price objective on shares of Collegium Pharmaceutical from $25.00 to $28.00 and gave the company a “buy” rating in a research note on Tuesday, December 5th. They noted that the move was a valuation call. HC Wainwright restated a “buy” rating and set a $21.00 price objective on shares of Collegium Pharmaceutical in a research note on Friday, November 17th. BidaskClub cut shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, January 9th. Piper Jaffray Companies restated a “buy” rating and set a $24.00 price objective on shares of Collegium Pharmaceutical in a research note on Thursday, December 7th. Finally, Jefferies Group lifted their price objective on shares of Collegium Pharmaceutical to $27.00 and gave the company a “buy” rating in a research note on Tuesday, December 5th. One investment analyst has rated the stock with a sell rating and seven have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $23.33.

TRADEMARK VIOLATION NOTICE: This story was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this story on another website, it was illegally stolen and republished in violation of United States and international trademark and copyright law. The legal version of this story can be accessed at https://www.dispatchtribunal.com/2018/01/20/collegium-pharmaceutical-inc-coll-chairman-michael-thomas-heffernan-sells-20000-shares.html.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting.

Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply